Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Ann Oncol ; 29(5): 1312-1319, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29554212

ABSTRACT

Background: Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and repeated vaccinations with tumor-lysate loaded dendritic cells shows efficacy against colon cancer mouse models. In the context of immunotherapy, radiotherapy can exert beneficial abscopal effects. Patients and methods: In this two-cohort pilot phase I study, 15 advanced cancer patients received two 4-week cycles of four intradermal daily doses of monocyte-derived dendritic cells preloaded with autologous tumor lysate and matured for 24 h with poly-ICLC (Hiltonol), TNF-α and IFN-α. On days +8 and +10 of each cycle, patients received intratumoral image-guided 0.25 mg injections of the dsRNA-analogue Hiltonol. Cyclophosphamide 600 mg/m2 was administered 1 week before. Six patients received stereotactic ablative radiotherapy (SABR) on selected tumor lesions, including those injected with Hiltonol. Expression of 25 immune-relevant genes was sequentially monitored by RT-PCR on circulating peripheral blood mononuclear cell (PBMCs) and serum concentrations of a cytokine panel were sequentially determined before and during treatment. Pre- and post-treatment PBMC from patients achieving durable stable disease (SD) were studied by IFNγ ELISPOT-assays responding to tumor-lysate loaded DC and by TCRß sequencing. Results: Combined treatment was, safe and well tolerated. One heavily pretreated castration-resistant prostate cancer patient experienced a remarkable mixed abscopal response to SABR+ immunotherapy. No objective responses were observed, while nine patients presented SD (five of them in the six-patient radiotherapy cohort). Intratumoral Hiltonol increased IFN-ß and IFN-α mRNA in circulating PBMC. DC vaccination increased serum IL-12 and IL-1ß concentrations, especially in patients presenting SD. IFNγ-ELISPOT reactivity to tumor lysates was observed in two patients experiencing durable SD. Conclusions: This radio-immunotherapy combination strategy, aimed at resembling viral infection in tumor tissue in combination with a dendritic-cell vaccine and SABR, is safe and shows immune-associated activity and signs of preliminary clinical efficacy.


Subject(s)
Cancer Vaccines/administration & dosage , Immunotherapy/methods , Neoplasms/therapy , Radiosurgery/methods , Adult , Aged , Antigens, Neoplasm/administration & dosage , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Carboxymethylcellulose Sodium/administration & dosage , Carboxymethylcellulose Sodium/analogs & derivatives , Combined Modality Therapy/methods , Cyclophosphamide/administration & dosage , Cytokines/immunology , Cytokines/metabolism , Dendritic Cells/immunology , Dendritic Cells/transplantation , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic/immunology , Humans , Injections, Intralesional , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Neoplasms/immunology , Poly I-C/administration & dosage , Polylysine/administration & dosage , Polylysine/analogs & derivatives , Response Evaluation Criteria in Solid Tumors
2.
Ann Oncol ; 21(12): 2420-2427, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20494963

ABSTRACT

BACKGROUND: Animal and clinical studies with plant-produced single-chain variable fragment lymphoma vaccines have demonstrated specific immunogenicity and safety. However, the expression levels of such fragments were highly variable and required complex engineering of the linkers. Moreover, the downstream processing could not be built around standard methods like protein A affinity capture. DESIGN: We report a novel vaccine manufacturing process, magnifection, devoid of the above-mentioned shortcomings and allowing consistent and efficient expression in plants of whole immunoglobulins (Igs). RESULTS: Full idiotype (Id)-containing IgG molecules of 20 lymphoma patients and 2 mouse lymphoma models were expressed at levels between 0.5 and 4.8 g/kg of leaf biomass. Protein A affinity capture purification yielded antigens of pharmaceutical purity. Several patient Igs produced in plants showed specific cross-reactivity with sera derived from the same patients immunized with hybridoma-produced Id vaccine. Mice vaccinated with plant- or hybridoma-produced Igs showed comparable protection levels in tumor challenge studies. CONCLUSIONS: This manufacturing process is reliable and robust, the manufacturing time from biopsy to vaccine is <12 weeks and the expression and purification of antigens require only 2 weeks. The process is also broadly applicable for manufacturing monoclonal antibodies in plants, providing 50- to 1000-fold higher yields than alternative plant expression methods.


Subject(s)
Cancer Vaccines/biosynthesis , Immunoglobulin Idiotypes/metabolism , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Plantibodies/metabolism , Agrobacterium tumefaciens/genetics , Agrobacterium tumefaciens/immunology , Agrobacterium tumefaciens/metabolism , Animals , Cancer Vaccines/genetics , Cancer Vaccines/immunology , Cancer Vaccines/isolation & purification , Cloning, Molecular , Efficiency , Gene Expression Regulation, Plant , Humans , Immunoglobulin Idiotypes/genetics , Immunoglobulin Idiotypes/immunology , Individuality , Mice , Mice, Inbred C3H , Plantibodies/genetics , Plantibodies/isolation & purification , Plants, Genetically Modified/genetics , Plants, Genetically Modified/immunology , Plants, Genetically Modified/metabolism , Time Factors , Vaccines, Synthetic/biosynthesis , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/isolation & purification
3.
Curr Pharm Des ; 16(3): 300-7, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20109139

ABSTRACT

After twenty years of use in humans, customized idiotypic vaccination yet remains a non-approved, experimental therapeutic option for patients with lymphoma and myeloma. Potentially applicable to all B-cell malignancies whose cells express a clonal immunoglobulin or its epitopes on their surface, this treatment is designed to prevent disease recurrence or progression. Mostly used in follicular lymphoma patients so far, idiotype vaccines have clearly shown biological efficacy, clinical efficacy and clinical benefit in this setting, although no study aiming at regulatory approval of the procedure has been able to meet its main clinical endpoints. In mantle cell lymphoma, only biological efficacy has been proven for idiotypic vaccination, while in multiple myeloma a limited number of studies support the notion of biological and perhaps even clinical efficacy, although no credible evidence of clinical benefit has still emerged. Idiotype vaccines have been produced and administered in a number of substantially different manners. Therefore, the results of most clinical trials cannot be easily compared, and even less pooled together in meaningful meta-analyses. A more creative and yet scientifically sound way to design clinical trials of customized active immunotherapies will be key to the future development of idiotype vaccines, particularly considering that we currently lack any clinical or biological indicator to possibly predict which patients are more likely to respond to idiotypic vaccination from an immunologic point of view. This review aims at summarizing the multifaceted success achieved by idiotype vaccines, as well as at outlining the challenges awaiting them in the near future: how to improve feasibility, immunogenicity and efficacy, as well as how to confirm benefit and gain regulatory approval.


Subject(s)
Cancer Vaccines/immunology , Lymphoma, Non-Hodgkin/therapy , Multiple Myeloma/therapy , Clinical Trials as Topic , Epitopes/immunology , Humans , Immunoglobulin Idiotypes/immunology , Lymphoma, Non-Hodgkin/immunology , Multiple Myeloma/immunology
4.
An Sist Sanit Navar ; 32(1): 61-73, 2009.
Article in Spanish | MEDLINE | ID: mdl-19430512

ABSTRACT

Follicular lymphoma is the second most prevalent non-Hodgkin lymphoma, representing 20% of all lymphomas. Follicular lymphoma is an indolent disease with a slow progression in which, although exhibiting a good response to treatment, relapse is very frequent and complete remission is not easy to maintain. Therefore, the disease is regarded as incurable. The search for new therapeutic strategies, together with a better understanding of the immune system, has led to the emergence of a new treatment named immunotherapy. Follicular lymphoma is a malignancy suitable for this kind of treatment given the fact that it is characterized by presenting a unique tumour-specific antigen: the idiotype of the monoclonal immunoglobulin displayed on the membrane of tumour cells. Several studies have been conducted to test immunotherapy as complementary to conventional treatment. In a previous study by our group, a clear benefit was evident is obtained after idiotypic vaccination, when an adequate immunization of the patient is obtained, in comparison to chemotherapy alone. In this sense, analysis is needed of whether idiotypic vaccination can produce not only long-lasting and complete remission, but even cure. It would be of great interest to consider an optimisation of the experimental design of clinical trials, an improvement of vaccine production, and the study of the molecular mechanisms of the tumour cell which modify the target immunoglobulin.


Subject(s)
Cancer Vaccines/therapeutic use , Immunoglobulin Idiotypes/therapeutic use , Lymphoma, Follicular/drug therapy , Forecasting , Humans , Immunotherapy
5.
An. sist. sanit. Navar ; 32(1): 61-73, ene.-abr. 2009. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-61433

ABSTRACT

El linfoma folicular (LF) está considerado como elsegundo tipo de linfoma no-Hodgkin más común, representandomás del 20% del total de los linfomas. Es unaenfermedad de progresión lenta y curso indolente enla que, a pesar de la buena respuesta al tratamiento,las recaídas son muy frecuentes y cada vez es más difícilconseguir respuestas completas. Por ello, se puedeconsiderar que hasta el momento, el LF es incurable.La búsqueda continua de nuevas estrategias terapéuticasen enfermedades neoplásicas, junto con un mejorconocimiento del sistema inmunitario, ha llevado ala aparición de una nueva disciplina, conocida con elnombre de inmunoterapia, que aprovecha la capacidaddel sistema inmunitario de atacar lo extraño sin dañarlo propio. El LF es un tumor muy apropiado para estetipo de tratamiento por presentar un antígeno específicode tumor: el idiotipo de la inmunoglobulina monoclonalexpresada en la membrana de todas las célulastumorales. Se han realizado diversos estudios en losque se ha probado la inmunoterapia como tratamientocomplementario al tratamiento convencional. Recientemente,nuestro grupo ha publicado un estudio en el quese observa claramente que los resultados que se obtienentras la vacunación idiotípica, cuando se consigue lainmunización adecuada del paciente, son mejores quelos obtenidos con quimioterapia sola. En este sentido,es necesario seguir investigando para aclarar si la vacunaciónidiotípica pudiera no sólo mantener remisionescompletas duraderas en los pacientes vacunados, sinoincluso conseguir la curación de los mismos. Por ello,resulta interesante abordar un mejor planteamiento delos ensayos clínicos, la mejora de la producción de lavacuna y el estudio de mecanismos de la célula tumoralcapaces de modificar la inmunoglobulina específica del tumor(AU)


Follicular lymphoma is the second most prevalentnon-Hodgkin lymphoma, representing 20% of all lymphomas.Follicular lymphoma is an indolent diseasewith a slow progression in which, although exhibitinga good response to treatment, relapse is very frequentand complete remission is not easy to maintain. Therefore,the disease is regarded as incurable. The searchfor new therapeutic strategies, together with a betterunderstanding of the immune system, has led to theemergence of a new treatment named immunotherapy.Follicular lymphoma is a malignancy suitable for thiskind of treatment given the fact that it is characterizedby presenting a unique tumour-specific antigen: theidiotype of the monoclonal immunoglobulin displayedon the membrane of tumour cells. Several studies havebeen conducted to test immunotherapy as complementaryto conventional treatment. In a previous study byour group, a clear benefit was evident is obtained afteridiotypic vaccination, when an adequate immunizationof the patient is obtained, in comparison to chemotherapyalone. In this sense, analysis is needed of whetheridiotypic vaccination can produce not only long-lastingand complete remission, but even cure. It would be ofgreat interest to consider an optimisation of the experimentaldesign of clinical trials, an improvementof vaccine production, and the study of the molecularmechanisms of the tumour cell which modify the targetimmunoglobulin(AU)


Subject(s)
Humans , Lymphoma, Follicular/therapy , Immunotherapy/methods , Cancer Vaccines/therapeutic use , Glycosylation , Lymphoma, Non-Hodgkin/immunology , Proto-Oncogene Proteins c-bcl-2/analysis , Alternative Splicing/immunology
6.
Oncogene ; 26(25): 3594-602, 2007 May 28.
Article in English | MEDLINE | ID: mdl-17530013

ABSTRACT

As a cancer immunotherapy tool, idiotypes (Ids) have been used in different ways over the last three decades, depending on the actual human tumor cell target. It all started with passive, monoclonal, anti-Id antibody treatment of B-cell lymphoma, a setting in which results were tantalizing, but logistics unsustainable. It then moved toward the development of anti-Id vaccines for the treatment of the same tumors, a setting in which we have recently provided the first formal proof of principle of clinical benefit associated with the use of a human cancer vaccine. Meanwhile, it also expanded in the direction of exploiting the antigenic mimicry of some Ids with Id-unrelated, tumor-associated antigens for the immunotherapy of a number of solid tumors, a setting in which clinical results are still far from being consolidated. All in all, over the years Id-based immunotherapy has paved the way for a number of seminal therapeutic improvements for cancer patients, including the development of most if not all Id-unrelated monoclonal antibodies that have recently revolutionized the field.


Subject(s)
Antibodies, Anti-Idiotypic/immunology , Antibodies, Anti-Idiotypic/therapeutic use , Immunotherapy , Neoplasms/immunology , Neoplasms/therapy , Animals , Antibodies, Neoplasm/immunology , Antibodies, Neoplasm/therapeutic use , Cancer Vaccines , Humans , Neoplasms/pathology
7.
Inmunología (1987) ; 24(1): 23-32, ene.-mar. 2005. tab
Article in English | IBECS | ID: ibc-93536

ABSTRACT

Una serie de circunstancias históricas han otorgado a las células dendríticas un lugar importante en la inmunoterapia antitumoral. El descubrimiento de su papel fundamental en la presentación antigénica ha propiciado su uso como adyuvantes en protocolos de vacunación en modelos tumorales de ratón. En estos modelos se llegaron a obtener remisiones tumorales. A finales de los años 90 la coincidencia de (i) estos prometedores resultados preclínicos, (ii) la disponibilidad en hospitales de áreas de terapiacelular (desarrolladas sobre todo para transplantes de médula ósea y (iii) protocolos de cultivo sencillos para diferenciar células dendríticas a partir de monocitos o precursores mieloides han impulsado la realización de múltiples ensayos clínicos. Los primeros datos clínicos no cumplieron las expectativas, pero se están extrayendo conclusiones sobre la actividad biológica e incluso se han obtenido algunos casos de respuestas clínicas en pacientes con cánceres avanzados. En cualquier caso, algunos de los ensayos que mejores resultados estaban obteniendo se encuentran bajo sospecha de fraude científico y otros buenos resultados obtenidos en los grupos piloto no se han reproducido cuando se han utilizado los mismos protocolos en grupos más amplios de pacientes.La situación actual del campo puede ser vista como una botella medio llena o medio vacía. En cualquier caso, se necesita mejorarla potencia terapéutica a nivel preclínico incluso con el riesgo de efectos adversos (AU)


A set of historical circumstances has centred the field of cancer immunotherapy on dendritic cells (DC). The discovery of their central role in antigen presentation for immunization gave rise to their use as adjuvants for cancer vaccination in transplantable tumour models in mice. Tumour rejections of experimental transplantable tumour models were achieved. During the late 90s concurrence of (i) this encouraging preclinical data, (ii) the availability of hospital cell therapy facilities that have been mainly set up for bone marrow transplantation and (iii) simple culture means to differentiate DC from monocytes or myeloid precursors spurred many clinical trials worldwide. Early clinical experience has not met the great expectations raised, but many lessons are being learned in terms of biological activity and cases of clinical response in advanced cases are routinely reported. However, some of the trials that reported the most encouraging clinical responses have confronted controversy due to scientific misconduct orto accumulation of successful cases in the pilot groups of patients that were not so reproducible when more patients were studied under the same protocols. The current status of the field could be seen as a half empty or a half full bottle. In either case, improvements are needed from the lab bench to increase therapeutic potency, even at the risk of side effects (AU)


Subject(s)
Humans , Dendritic Cells/immunology , Immunotherapy/methods , Neoplasms/drug therapy , Cell- and Tissue-Based Therapy/methods , Adjuvants, Immunologic/pharmacokinetics
8.
Clin Exp Dermatol ; 30(5): 541-5, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16045689

ABSTRACT

Matrix metalloproteinases (MMP)-2 and -9 have been implicated in malignant tumour progression, partly because they degrade collagen type IV, a major component of basement membranes. Biopsy specimens from 56 patients with primary melanoma and 7 with cutaneous or nodal metastases were studied by immunohistochemistry. Of 39 patients with estimated good prognosis, 70.5% of melanomas were negative for MMP-2, compared with only 47% of 17 melanomas in patients who developed metastasis during the 3-year follow-up. All skin and nodal metastases were negative for MMP-2 and positive for MMP-9. Of 14 thick melanomas, 9 were mostly positive for MMP-2 expression, suggesting a possible association with the invasiveness of the melanoma. MMP-2 and MMP-9 plasma levels were analysed in another 29 patients with melanoma (10 stage I and II, 9 stage III, and 10 stage IV) and in 10 healthy controls. No difference in MMP-9 plasma levels was found among the groups. Higher MMP-2 concentrations were observed in patients with metastatic disease (stage IV) than in those with primary melanoma (stage I) or in controls. Serial levels in two patients who passed from stage I to stage III or IV showed no significant difference in MMP-2 or -9 values. We conclude that MMP-2 expression might be associated with progression of the melanoma. Circulating MMP-2 and -9 levels have shown low sensitivity and specificity, so they do not seem to be good tumour markers in patients with melanoma.


Subject(s)
Biomarkers, Tumor/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Melanoma/enzymology , Skin Neoplasms/enzymology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Disease Progression , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Male , Matrix Metalloproteinase 2/blood , Matrix Metalloproteinase 9/blood , Melanoma/pathology , Melanoma/secondary , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Skin Neoplasms/pathology , Statistics, Nonparametric
9.
Inmunología (1987) ; 24(1): 23-32, ene.-mar. 2005.
Article in En | IBECS | ID: ibc-043669

ABSTRACT

Una serie de circunstancias históricas han otorgado a las célulasdendríticas un lugar importante en la inmunoterapia antitumoral.El descubrimiento de su papel fundamental en la presentaciónantigénica ha propiciado su uso como adyuvantes en protocolosde vacunación en modelos tumorales de ratón. En estosmodelos se llegaron a obtener remisiones tumorales. A finales delos años 90 la coincidencia de (i) estos prometedores resultadospreclínicos, (ii) la disponibilidad en hospitales de áreas de terapiacelular (desarrolladas sobre todo para transplantes de médulaósea y (iii) protocolos de cultivo sencillos para diferenciar célulasdendríticas a partir de monocitos o precursores mieloides hanimpulsado la realización de múltiples ensayos clínicos. Los primerosdatos clínicos no cumplieron las expectativas, pero se estánextrayendo conclusiones sobre la actividad biológica e incluso sehan obtenido algunos casos de respuestas clínicas en pacientescon cánceres avanzados. En cualquier caso, algunos de los ensayosque mejores resultados estaban obteniendo se encuentran bajosospecha de fraude científico y otros buenos resultados obtenidosen los grupos piloto no se han reproducido cuando se hanutilizado los mismos protocolos en grupos más amplios de pacientes.La situación actual del campo puede ser vista como una botellamedio llena o medio vacía. En cualquier caso, se necesita mejorarla potencia terapéutica a nivel preclínico incluso con el riesgode efectos adversos


A set of historical circumstances has centred the field of cancerimmunotherapy on dendritic cells (DC). The discovery of theircentral role in antigen presentation for immunization gave rise totheir use as adjuvants for cancer vaccination in transplantabletumour models in mice. Tumour rejections of experimental transplantabletumour models were achieved. During the late 90s concurrenceof (i) this encouraging preclinical data, (ii) the availabilityof hospital cell therapy facilities that have been mainly set upfor bone marrow transplantation and (iii) simple culture meansto differentiate DC from monocytes or myeloid precursors spurredmany clinical trials worldwide. Early clinical experience hasnot met the great expectations raised, but many lessons are beinglearned in terms of biological activity and cases of clinical responsein advanced cases are routinely reported. However, someof the trials that reported the most encouraging clinical responseshave confronted controversy due to scientific misconduct orto accumulation of successful cases in the pilot groups of patientsthat were not so reproducible when more patients were studiedunder the same protocols. The current status of the field could beseen as a half empty or a half full bottle. In either case, improvementsare needed from the lab bench to increase therapeuticpotency, even at the risk of side effects


Subject(s)
Humans , Dendritic Cells/immunology , Immunotherapy/methods , Neoplasms/immunology , Cell- and Tissue-Based Therapy
10.
Rev Med Univ Navarra ; 48(3): 14-23, 2004.
Article in Spanish | MEDLINE | ID: mdl-15622921

ABSTRACT

Cancer vaccines are conceived as therapeutic tools, in contrast to the prophylactic vaccines used to fight against infectious diseases. Among the most potent therapeutic vaccines, anti-idiotype vaccination is directed against the tumor idiotype, the only well-characterized tumor antigen displayed in neoplastic B-cells. Anti-idiotype vaccines have demonstrated clinical benefit against follicular lymphoma and are currently being evaluated in two different phase III clinical trials. Additional emerging strategies, which include the use of dendritic cells and the production of vaccines via molecular means will surely allow us to draw important conclusions concerning the treatment of cancer patients.


Subject(s)
Cancer Vaccines/immunology , Neoplasms/drug therapy , Clinical Trials as Topic , Forecasting , Humans , Immunoglobulin Idiotypes/immunology , Immunotherapy/trends , Neoplasms/immunology
11.
An Sist Sanit Navar ; 27(1): 45-62, 2004.
Article in Spanish | MEDLINE | ID: mdl-15146205

ABSTRACT

The continuous search for therapeutic approaches that improve the conventional treatments of neoplasms, together with an improved understanding of the immune system, has led in recent years to the development of Immunotherapy. Basically, a distinction can be made between two forms of immunotherapy: passive immunotherapy, which consists in the transfer of antibodies or cells previously generated in vitro that are directed against the tumour, and active immunotherapy, which attempts to activate in vivo the immune system and induce it to elaborate a specific response against the tumor antibodies. Hematological neoplasms, specifically some B lymphomas, express in their membrane an immunoglobulin that is considered a specific antigen of the tumour, which is why these diseases have become the ideal target for immunotherapy treatments. There are many alternatives, ranging from protein vaccines, which have already shown clinical benefits, to those of the second generation, which make use of the new techniques of molecular biology to increase the efficacy of the vaccines and obtain their production in a quicker and less costly way, but with which there are not yet definitive clinical results.


Subject(s)
Cancer Vaccines/therapeutic use , Immunotherapy, Active/methods , Lymphoma, Follicular/drug therapy , Clinical Trials as Topic , Dendritic Cells/immunology , Humans , Immunization, Passive , Lymphoma, Follicular/immunology
12.
An. sist. sanit. Navar ; 27(1): 45-62, ene. 2004. tab, ilus
Article in Es | IBECS | ID: ibc-32182

ABSTRACT

La continua búsqueda de abordajes terapéuticos que mejoren los tratamientos convencionales de las enfermedades neoplásicas junto con el mejor conocimiento del sistema inmunitario ha llevado en los últimos años al desarrollo de la inmunoterapia. Básicamente se pueden distinguir dos formas de inmunoterapia: la inmunoterapia pasiva, que consiste en la transferencia de anticuerpos o células previamente generados in vitro que se dirigen contra el tumor, y la inmunoterapia activa, que pretende activar in vivo el sistema inmunitario e inducirlo a elaborar una respuesta específica contra los antígenos tumorales. Las neoplasias hematológicas, concretamente algunos linfomas B, expresan en su membrana una inmunoglobulina que se considera un verdadero antígeno específico de tumor; por eso estas enfermedades se han convertido en la diana ideal de los tratamientos de inmunoterapia. Las alternativas son muchas, desde las vacunas proteicas que ya han demostrado beneficios clínicos, hasta las de segunda generación, que aprovechan las nuevas técnicas de biología molecular para aumentar la eficacia de las vacunas y conseguir su producción de forma más rápida y menos costosa, pero con las que todavía no hay resultados clínicos definitivos (AU)


Subject(s)
Immunotherapy, Active/methods , Immunotherapy, Active/trends , Immunotherapy, Active , Lymphoma, Follicular/diagnosis , Lymphoma, Follicular/therapy , Antibodies, Monoclonal/analysis , Antibodies, Monoclonal/isolation & purification , DNA/immunology , Hematologic Neoplasms/immunology , Hematologic Neoplasms/therapy , Immune System/physiopathology , Molecular Biology/methods , Dendritic Cells/immunology , Dendritic Cells/pathology , Immunotherapy/classification
13.
Rev. Med. Univ. Navarra ; 46(2): 24-28, 2002. tab, graf
Article in Spanish | IBECS | ID: ibc-157003

ABSTRACT

La posibilidad de utilizar células madre en el tratamiento de diversas enfermedades humanas como la diabetes, la enfermedad de Parkinson, la cardiopatía isquémica constituye uno de los retos mas importantes de la medicina moderna. Sin embargo, antes de que los resultados de los estudios con células madre se traduzcan clínicamente existen múltiples problemas que deben ser resueltos. A continuación trataremos de exponer algunos conceptos relacionados con las células madre y su potencial, centrándonos principalmente en las células madre adultas tal como han sido recientemente descritas por el grupo de Catherine Verfaillie. Además presentaremos resultados de alguno de los primeros estudios clínicos realizados con células madre adultas como forma de terapia regenerativa cardíaca. En dichos trabajos se han empleado células madre de músculo (células satélite) autólogas en pacientes con infarto de miocardio, inyectándose directamente dichas células en la periferia de la cicatriz secundaria al infarto (AU)


One of the most important challenges in modern medicine is the use of stem cells for the treatment of human disease such as diabetes, Parkinson´s disease or isquemic cardiomyopathy. A number of problems need to be solved before stem cells can be applied clinically. In this paper we will review some concepts related to the potential of stem cells, focusing on adult stem cells as they have recently been described by the group of Catherine Verfaillie. We will also present our initial clinical results using adult stem cells for cardiac regenerative therapy. In the studies mentioned above, autologous muscle stem cells (satelite cells) were infused directly in the periphery of the scar tissue of the infarct. We describe the technique for ex vivo expansion and purification of muscle stem cells (AU)


Subject(s)
Humans , Male , Female , Stem Cells/physiology , Regenerative Medicine/methods , Regenerative Medicine/trends , Myocardial Infarction/rehabilitation , Myocardial Infarction/therapy , Flow Cytometry/methods , Flow Cytometry , Cell Self Renewal/physiology , Myoblasts/physiology , Myoblasts, Cardiac/physiology , Myoblasts, Cardiac/ultrastructure
14.
Acta Haematol ; 105(3): 137-42, 2001.
Article in English | MEDLINE | ID: mdl-11463986

ABSTRACT

Dose intensity has been related to clinical outcome in several solid tumors. We studied the influence of clinical and cellular parameters on dose intensity received in a series of 53 patients with metastatic breast cancer or advanced ovarian cancer. They received courses of cisplatin 120 mg/m(2) plus etoposide 600 mg/m(2) alternating every 14 days with ifosfamide 8 g/m(2) plus paclitaxel 200--350 mg/m(2). Blood stem cell support was administered after every course except for the first one. Patients with excellent mobilization underwent immunomagnetic selection of CD34+ cells. We found a significant inverse correlation between the CD34+ cell dose infused and the delay for the administration of the next cycle. A CD34+ cell dose between 1.5 and 5 x 10(6)/kg per cycle was found to be feasible and was followed by a median delay of 1 day (not different from doses above 5 x 10(6)/kg). Three factors independently predicted the actually received dose intensity in a multiple regression model (R(2) = 0.4): previous autologous transplantation, eligibility for immunomagnetic selection (excellent response to mobilization) and median CD34+ cell dose received along the treatment.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/standards , Ovarian Neoplasms/therapy , Stem Cells/immunology , Adult , Antigens, CD34/analysis , Cell Count , Cisplatin/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Etoposide/administration & dosage , Female , Hematopoietic Stem Cell Transplantation/methods , Humans , Ifosfamide/administration & dosage , Immunomagnetic Separation , Middle Aged , Models, Biological , Paclitaxel/administration & dosage , Time Factors , Transplantation, Autologous , Treatment Outcome
15.
Ann Oncol ; 12(10): 1479-84, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11762822

ABSTRACT

BACKGROUND: The complementarity determining region 3 (CDR3) of the immunoglobulin (Ig) heavy chain variable region (VH) is the most reliable molecular fingerprint for most if not all human B cells. The nucleotide sequence encoding for any B-cell tumor-specific VH CDR3 is currently identified by PCR sequencing based on procedures involving the usage of either radioactive materials, patient/family-specific primers, or bacterial cloning. PATIENTS AND METHODS: In six consecutive patients with follicular lymphoma we assessed the feasibility of a method that allows for identification of the tumor-specific VH CDR3 using consensus primers while avoiding both radioactive materials and bacterial cloning procedures. RESULTS: The tumor-specific VH CDR3 was successfully identified in all six patients in nearly half the time typically required by any other method currently utilized. The feasibility of the proposed method was not significantly affected either by the tumor-specific Ig isotype, or by the tumor infiltration in the original biopsy specimen. In the three patients for whom tumor specimen-derived hybridomas were available, the tumor-specific VH CDR3 was also found in at least 8 of 10 of them. CONCLUSIONS: The proposed method allows the ability to quickly identify the B-cell tumor-specific VH CDR3 using consensus primers while avoiding radioactive materials and bacterial cloning procedures.


Subject(s)
Biomarkers, Tumor/analysis , DNA Fingerprinting , DNA, Neoplasm/analysis , Immunoglobulin Heavy Chains/genetics , Lymphoma, B-Cell/genetics , Lymphoma, Follicular/genetics , Base Sequence , DNA Primers , DNA, Complementary , Humans , Hybridomas , Lymphoma, B-Cell/pathology , Lymphoma, Follicular/pathology , Molecular Sequence Data , Polymerase Chain Reaction , Sensitivity and Specificity , Sequence Analysis, DNA , Software , Time Factors
17.
Inmunología (1987) ; 19(4): 134-138, oct. 2000. ilus
Article in Es | IBECS | ID: ibc-4447

ABSTRACT

La última década ha sido testigo de un debate sobre el status de la respuesta inmunitaria específica frente a antígenos asociados a células malignas en pacientes portadores de tumores. Algunos sostienen que existe una situación de tolerancia producto de la anergia o deleción de los clones linfocitarios relevantes, mientras que los modelos experimentales demuestran a menudo que existe un estado de ignorancia en el Sistema Inmunitario, en el que coexisten elementos re s p o n d e d o res y antígenos sin que ocurra tolerización ni respuesta efectora medible. Varios factores pueden explicar este estado, pero el que pare c e tener más importancia es la falta de acceso en condiciones apropiadas de las células del Sistema Inmunitario a las células malignas. En algunos casos la ignorancia inmunológica no puede ser distinguida de cierto grado de tolerancia periférica parcial. Proponemos que la inyección intratumoral de linfocitos T o NK y/o de células dendríticas con fines inmunoterapéuticos puede romper estos mecanismos de ignorancia o tolerancia parcial (AU)


Subject(s)
Animals , Humans , Immune System/cytology , Antigens, Neoplasm/immunology , T-Lymphocytes , Killer Cells, Natural , Dendritic Cells , Immune Tolerance
18.
Cardiovasc Pathol ; 9(3): 153-9, 2000.
Article in English | MEDLINE | ID: mdl-10989315

ABSTRACT

Early cardiac allograft failure (ECAF) was defined as acute allograft failure in the early transplant period. The aim of this study is to elucidate the clinicopathological and immunohistochemical characteristics and the role of apoptosis in ECAF in nine patients. We reviewed preoperative clinical data and morphological data at the time of autopsy or retransplantation. We also performed TUNEL assay and immunohistochemistry to study fibronectin and tubulin beta-II. The average recipient and donor age was 48 +/- 10.3 and 28 +/- 7.11 respectively. Seven patients died at a mean time of 26 hours. The remaining two patients underwent retransplantation and are alive. The mean cold ischemic time was 124. 1 +/- 44.5 minutes. No patient had a panel reactive antibody >15% and lymphocytic crossmatch was positive in one case. All cases had grade 2-3 of coagulative necrosis, which correlated positively with fibonectin accumulation in myocyte cytoplasm, and cytoplasmic tubulin loss (p < 0.05). TUNEL technique showed in all cases some degree of DNA strand breaks in cardiomyocytes. Endothelium DNA strand breaks were seen in seven cases. Patients transplanted because of idiopathic dilated cardiomyopathy had a significantly higher degree of DNA strand breaks in cardiomyocytes and endothelial cells (p = 0.03 and p = 0.02) than those transplanted because of ischemic cardiomyopathy. These results indicate that ECAF may be caused by ischemic-reperfusion damage to the donor heart assessed by myocyte coagulative necrosis, fibronectin accumulation in myocytes, tubulin loss, and DNA strand breaks of cardiomyocytes and endothelium. The use of a combination of these techniques might be appropriate in the diagnosis of ECAF in endomyocardial biopsies when it is suspected clinically.


Subject(s)
Apoptosis/physiology , Graft Rejection/pathology , Heart Transplantation/pathology , Adult , Female , Fibronectins/metabolism , Graft Rejection/etiology , Heart Septum/metabolism , Heart Septum/pathology , Heart Transplantation/adverse effects , Heart Ventricles/metabolism , Heart Ventricles/pathology , Humans , Immunoenzyme Techniques , In Situ Nick-End Labeling , Male , Middle Aged , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocardium/metabolism , Myocardium/pathology , Transplantation, Homologous , Tubulin/metabolism
19.
Clin Immunol ; 96(3): 230-5, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10964541

ABSTRACT

The use of flow cytometry to detect intracellular cytokines at the single cell level has the potential to quantify cytokine production together with the possibility of phenotypic identification of the cell population concerned. The unbalanced presence of intracellular cytokines produced by T cells has been recognized in some pathological conditions. To better address this issue, we studied the production of IFN-gamma and IL-4 in CD4(+) and CD8(+high) T cells in healthy donors of a broad range of age (17-62 years). Given that an increase of IFN-gamma and IL-4 with aging had been reported by some authors in healthy controls, we have performed a multivariate analysis to assess the intrinsic role of aging or of other external factors, such as chronic antigenic exposures (i.e., viruses), over the cytokine production of phenotypically characterized T cells. In this respect we show that, mainly in CD8(+high) T cells, the production of IFN-gamma is directly correlated with age. Besides, the cytokine production correlates with the CD8(+high)CD28(-)CD57(+) T-cell population, which we have recently reported elevated in aged individuals. Perhaps this T-cell subpopulation plays a regulatory role as a Tc1 response in aging individuals.


Subject(s)
Aging/metabolism , CD28 Antigens/analysis , CD57 Antigens/analysis , CD8-Positive T-Lymphocytes/cytology , Interferon-gamma/metabolism , Lymphocyte Subsets/metabolism , Adolescent , Adult , Aging/physiology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cytomegalovirus/physiology , Flow Cytometry , Humans , Lymphocyte Subsets/immunology , Middle Aged
20.
Clin Exp Immunol ; 115(3): 521-5, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10193428

ABSTRACT

In this study we have examined intracellular cytokines in peripheral blood mononuclear cells (PBMC) of MS patients by flow cytometry (cytokine flow cytometry). MS progressive patients showed an increased number of cells producing interferon-gamma (IFN-gamma) after activation with phorbol 12-myristate 13-acetate and ionomycin, compared with patients with clinically inactive forms (P < 0001) and with healthy controls (P = 0001). These cells belonged to the CD4+ and CD8+ subsets in similar proportions. Clinically inactive patients showed a lower level of cells producing IL-2 than controls (P = 0.03) and active MS patients (P = 0.03). Most IL-2-producing cells were CD4+ lymphocytes, although a small part of the IL-2 was also produced by CD8+ cells. The percentage of cells producing simultaneously IL-2 and IFN-gamma was increased in active MS and they were mainly CD4+ lymphocytes. No differences in the production of IL-4 were observed between groups. However, we found an increased IL-10 production in clinically active MS patients (P = 0.03). Treatment with IFN-beta of active MS patients showed lower levels of cytokines when compared with untreated MS patients. This methodological approach could help in the follow up and therapeutic monitoring of MS patients.


Subject(s)
Cytokines/biosynthesis , Flow Cytometry/methods , Multiple Sclerosis/immunology , Adult , Aged , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Case-Control Studies , Female , Humans , In Vitro Techniques , Interferon-beta/therapeutic use , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Interleukin-2/biosynthesis , Ionomycin/pharmacology , Lymphocyte Activation , Male , Middle Aged , Multiple Sclerosis/therapy , Phenotype , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...